Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

12548

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Epilepsy, Epilepsy (Treatment Refractory)
Interventions: Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system); Device
Lead sponsor: Epiminder America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 19 more

Conditions: Non-obstructive Hypertrophic Cardiomyopathy
Interventions: Ninerafaxstat 200mg MR, Placebo; Drug
Lead sponsor: Imbria Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 26
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 21 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 12 more

Conditions: Asthma
Interventions: GSK5784283, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 53
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 45 more

Conditions: Advanced Cancer, Metastatic Cancer
Interventions: T-DXd; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Miami, Florida • Durham, North Carolina

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib oral treatment, Ocrelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 45
States / cities: Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 40 more

Conditions: Alopecia Areata
Interventions: Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Encinitas, California • Miami, Florida • Skokie, Illinois + 13 more

Conditions: Cancer Survivorship
Interventions: Supervised Exercise and Diet Program, Unsupervised Exercise and Diet Program; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Miami, Florida • Boston, Massachusetts

Conditions: Stroke, Acute
Interventions: Conventional Triage for Mechanical Thrombectomy, Direct Transfer to Angiography Suite (DTAS; Other
Lead sponsor: Santiago Ortega Gutierrez; Other
Eligibility: 18 Years and older
Enrollment: 2,039 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: New Haven, Connecticut • Hollywood, Florida • Miami, Florida + 12 more

Conditions: Solid Cancer
Interventions: R-DXd, Paclitaxel, Topotecan, PLD; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 45
States / cities: Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 33 more

Conditions: HR+/HER2- Breast Cancer
Interventions: BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 84
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 79 more

Conditions: Lymphoma
Interventions: Health Education Program, SMART3RP-Lymphoma; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • Salt Lake City, Utah

Clinical trials in Miami, Florida

Filter and sort this location

Live official records

Diagnosing Epilepsy To EffeCT Change

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study

Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship